1. Home
  2. CLLS vs SAAQ Comparison

CLLS vs SAAQ Comparison

Compare CLLS & SAAQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$3.22

Market Cap

394.4M

Sector

Health Care

ML Signal

HOLD

SAAQ

Space Asset Acquisition Corp. Class A Ordinary Shares

N/A

Current Price

$10.42

Market Cap

342.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CLLS
SAAQ
Founded
1999
2025
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
394.4M
342.7M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
CLLS
SAAQ
Price
$3.22
$10.42
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$8.33
N/A
AVG Volume (30 Days)
32.4K
37.4K
Earning Date
05-08-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.35
$9.88
52 Week High
$5.48
$11.10

Technical Indicators

Market Signals
Indicator
CLLS
SAAQ
Relative Strength Index (RSI) 37.61 49.12
Support Level $3.05 $10.19
Resistance Level $3.83 $10.55
Average True Range (ATR) 0.17 0.25
MACD -0.03 -0.03
Stochastic Oscillator 24.19 13.64

Price Performance

Historical Comparison
CLLS
SAAQ

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

About SAAQ Space Asset Acquisition Corp. Class A Ordinary Shares

Space Asset Acquisition Corp is a blank check company.

Share on Social Networks: